Abstract
Sulfotransferase (SULT) function has been well studied in healthy human subjects by quantifying mRNA and protein expression and determining enzyme activity with probe substrates. However, it is not well known if sulfotransferase activity changes in metabolic and liver disease, such as diabetes, steatosis, or cirrhosis. Sulfotransferases have significant roles in the regulation of hormones and excretion of xenobiotics. In the present study of normal subjects with nonfatty livers and patients with steatosis, diabetic cirrhosis, and alcoholic cirrhosis, we sought to determine SULT1A1, SULT2A1, SULT1E1, and SULT1A3 activity and mRNA and protein expression in human liver tissue. In general, sulfotransferase activity decreased significantly with severity of liver disease from steatosis to cirrhosis. Specifically, SULT1A1 and SULT1A3 activities were lower in disease states relative to nonfatty tissues. Alcoholic cirrhotic tissues further contained lower SULT1A1 and 1A3 activities than those affected by either of the two other disease states. SULT2A1, on the other hand, was only reduced in alcoholic cirrhotic tissues. SULT1E1 was reduced both in diabetic cirrhosis and in alcoholic cirrhosis tissues, relative to nonfatty liver tissues. In conclusion, the reduced levels of sulfotransferase expression and activity in diseased versus nondiseased liver tissue may alter the metabolism and disposition of xenobiotics and affect homeostasis of endobiotic sulfotransferase substrates.
Footnotes
- Received January 14, 2013.
- Accepted June 13, 2013.
This work was supported in part by the University of Rhode Island (URI) Foundation (R.S.K.); the URI Council for Research (R.S.K.); a URI Graduate Fellowship (E.B.Y.); and a Summer Undergraduate Research Fellowship from RI-INBRE (K.L.N.).
This work also was supported in part by the National Institutes of Health [Grants 5R-01ES-016042-03, 3R-01ES-016042-2S2, and 5K-22ES-013782-03] (to A.L.S.); and by the Rhode Island IDeA Network of Biomedical Research Excellence [P20RR016457-10] from the National Institutes of Health National Center for Research Resources (to R.S.K. and A.L.S.).
A portion of this work was previously presented: Emine Bihter Yalçin, Karissa Neira, Renae Gupta, Angela L. Slitt and Roberta S. King (2011) Sulfotransferase expression and activity is altered by human metabolic disease. 17th North America Regional International Society for the Study of Xenobiotics (ISSX) Meeting; 2011 Oct 16–20; Atlanta, GA. P78. Drug Metab Rev 42(S2).
↵This article has supplemental material available at dmd.aspetjournals.org.
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|